'Reproductive' Industry Hands Out Abortion Pills, Withholds Fertility Drugs

The reproductive health industry is facing criticism for its focus on abortion services while neglecting fertility treatments, particularly for older women. Critics argue that while abortion pills are readily available, fertility medications like oral progesterone are often withheld, leaving many women struggling with infertility without necessary support.

On September 30, the FDA approved the use of generic Mifepristone, a widely used abortion drug. This decision prompted U.S. representatives to express concerns, urging Health Secretary Robert F. Kennedy Jr. to investigate what they termed a 'reckless decision.' According to a 2021 study by the National Library of Medicine, Mifepristone has been linked to significant health risks, including fatalities. The FDA has classified it as safe, despite reports of 36 deaths associated with the drug in 2024 alone.

The Guttmacher Institute reported that over one million abortions were performed in the U.S. last year, with a notable increase in the use of Mifepristone through telehealth services. This trend raises questions about the accessibility of fertility treatments, particularly for women in their late 30s and early 40s who may require progesterone to support healthy pregnancies.

Progesterone is a hormone essential for maintaining a healthy uterine lining, yet many doctors are hesitant to prescribe it due to a lack of conclusive studies linking progesterone deficiencies to miscarriages. Harvard Health notes that progesterone levels decline as women age, which can impact fertility. Despite this, prescriptions for progesterone are often limited to fertility specialists, leaving many women without access to this critical treatment.

The CDC reports that over 13 percent of women aged 15-49 experience fertility issues, a figure that rises for married women. With many couples choosing to marry later in life, the need for effective fertility treatments is becoming increasingly urgent. However, the reproductive health field appears to prioritize abortion services over supporting women seeking to conceive.

Online discussions among women experiencing fertility challenges reveal a common theme: many have had to advocate for progesterone prescriptions after experiencing multiple miscarriages. The reluctance of some healthcare providers to prescribe this hormone raises concerns about the overall focus of the reproductive health industry.

While abortion medications are widely available, the barriers to accessing progesterone prescriptions remain. The Mayo Clinic indicates that the most common side effects of oral progesterone are mild, with no reported deaths linked to its use. In contrast, the risks associated with Mifepristone have been well-documented, prompting calls for a reevaluation of the priorities within reproductive health.

Advocates argue that a balanced approach to women's health care should prioritize both fertility and abortion services. The current emphasis on abortion may overlook the needs of women who wish to conceive, particularly those facing age-related fertility challenges. As the conversation around reproductive health continues, many are calling for more research and a shift in focus towards supporting healthy pregnancies.

Jessica Marie Baumgartner is a homeschooling mother of five, co-op English teacher, and America First reporter for the Right Side Broadcasting Network and Mid Rivers Newsmagazine. Follow her on X: @jessmbaum.